Updated:
Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics, based in Sarasota, Florida, focuses on anti-infective drug development for indications where standard-of-care antibiotics are...
Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics, based in Sarasota, Florida, focuses on anti-infective drug development for indications where standard-of-care antibiotics are failing. Steven J. Parkinson, a veteran of drug development and licensing, has led the company as President and CEO through preclinical and early clinical-phase work on its bisphosphocin platform. Taffy Williams, the CFO, provides operational leadership and strategic financial management (per the firm's official communications). The firm identifies as a clinical-stage company, and its therapeutic strategy is built entirely around bisphosphocins. These synthetic antimicrobial compounds penetrate bacterial and fungal cell membranes and cause rapid cell death through physical disruption rather than interfering with a specific metabolic pathway. This mechanism of action, according to the company's published research, means pathogens cannot easily develop resistance through single-point mutations — a structural feature that differentiates it from most antibiotics and antifungals in development. Lakewood-Amedex's lead candidate, Nu-3, has been studied in Phase II trials for diabetic foot ulcers and has been granted Orphan Drug Designation by the FDA. Other pipeline candidates target indications including cystic fibrosis-associated respiratory infections and systemic fungal infections. Scale and team information remain thin; the company has not broadly disclosed headcount, annual deployment, or external financing rounds. Its last material public update came in mid-2023, when Parkinson discussed bisphosphocin mechanisms at an academic forum focused on antimicrobial resistance (per public record). The absence of a dedicated LinkedIn presence or frequent press releases suggests a lean operation prioritizing clinical development over market-facing communication, a common posture for pre-revenue biotech. Structurally, Lakewood-Amedex illustrates the private, patent-protected single-asset-platform bet that defines earlier-stage biotech investing but is rare among family-office backed entities with perpetual capital. Its narrow focus on a novel, non-metabolic mechanism of action isolates it from the typical me-too antibiotic development found in larger pharma pipelines. The lack of disclosed fundraising rounds also raises the question of whether the company is predominantly self-funded by its principals or a single backer, which would further differentiate its governance and risk posture from institutionally syndicated drug startups.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Sarasota
Corporate office
Sarasota, FL, United States
Principals
Steven J. Parkinson
President and Chief Executive Officer
Taffy Williams
Chief Financial Officer
Sector focus
Frequently asked questions
What is a bisphosphocin and why does it matter?
A bisphosphocin is a synthetic molecule that mimics bacterial and fungal DNA and disrupts cell membranes through a physical rather than metabolic mechanism. Lakewood-Amedex has built its entire pipeline around this platform because it makes acquired resistance far less likely — pathogens would need to fundamentally restructure their membranes to evade the drug, a far higher evolutionary barrier than a single-point mutation. This mode of action has attracted attention as standard antibiotics fail against multi-drug-resistant organisms.
What is Lakewood-Amedex's lead drug candidate?
The lead candidate is Nu-3, a topical bisphosphocin formulation studied in Phase II clinical trials for infected diabetic foot ulcers. The FDA has granted Nu-3 Orphan Drug Designation. The company has also published preclinical work on inhaled formulations for cystic fibrosis-associated lung infections and systemic candidates for invasive fungal disease.
Who runs Lakewood-Amedex?
Steven J. Parkinson serves as President and CEO. His background spans biopharmaceutical development, licensing, and commercialization. Taffy Williams is the Chief Financial Officer. The company operates without a large public-facing board or disclosed institutional syndicate, which is typical for privately held, earlier-stage therapeutics firms that may have a concentrated investor base.
Is Lakewood-Amedex publicly traded or venture-backed?
The company does not appear to be publicly traded, and no major institutional venture rounds have been disclosed (per public record). Its financing structure has not been detailed in public filings or press releases. This opaqueness could indicate self-funding by principals or a single-family capital source, though this remains an inference rather than a confirmed fact.
What differentiates Lakewood-Amedex from larger antibiotic developers?
Most antibiotic development focuses on modifying existing chemical classes or finding new metabolic inhibitors, where resistance can still evolve via target-site mutations. Lakewood-Amedex is one of the few companies pursuing a purely physical disruption mechanism that does not depend on a metabolic pathway. This approach places it in a narrow field alongside other 'resistance-proof' strategies, though it also means the company bears the full clinical and regulatory risk of a novel mechanism without a safety record in large patient populations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: